Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sadhana Nitro Chem Limited is an India-based specialty chemicals manufacturer focused on nitro-aromatic compounds and intermediates used in agrochemicals, pharmaceuticals, and dyes. The company operates manufacturing facilities in Gujarat and Maharashtra, serving domestic and export markets. The stock has experienced severe distress with a 93.5% decline over the past year, negative free cash flow of $0.5B against $0.9B in capex, and negative ROE of -18.7% despite maintaining 62.2% gross margins, suggesting operational challenges or asset impairments.
The company produces nitration-based specialty chemicals through batch processing at dedicated manufacturing facilities. Revenue is generated through long-term supply contracts with agrochemical and pharmaceutical companies, plus spot sales to dye manufacturers. Pricing power is moderate, tied to raw material costs (benzene, toluene, nitric acid) and customer switching costs. The 62.2% gross margin suggests value-added chemistry, but the 4.6% net margin indicates high fixed costs, interest burden (1.02 D/E ratio), or pricing pressure. Competitive advantage stems from regulatory approvals, technical expertise in nitration chemistry, and established customer relationships in regulated end-markets.
Agrochemical demand cycles in India and export markets, particularly monsoon-dependent crop protection chemical orders
Raw material cost volatility for benzene, toluene, and nitric acid, which directly impact gross margins given commodity-linked pricing
Capacity utilization rates at Gujarat and Maharashtra facilities - breakeven likely requires 65-75% utilization
Working capital management and debt servicing ability given negative free cash flow and 1.02 debt-to-equity ratio
Environmental compliance costs and regulatory approvals for nitration processes under Indian pollution control norms
Environmental regulations on nitration processes and effluent treatment are tightening globally, requiring ongoing capex for compliance and potentially limiting production flexibility
Chinese competition in commodity specialty chemicals has intensified, with lower-cost producers capturing market share in price-sensitive segments like dye intermediates
Customer consolidation in agrochemical and pharmaceutical sectors increases bargaining power and pricing pressure on intermediate suppliers
Larger integrated chemical companies (Aarti Industries, Deepak Nitrite) have superior scale, backward integration, and R&D capabilities for next-generation intermediates
Import competition from China and other Asian producers during demand downturns, particularly in non-regulated commodity grades
Customer backward integration risk as large agrochemical companies develop in-house intermediate production to secure supply chains
Negative free cash flow of $0.5B against $0.9B capex creates liquidity pressure and potential covenant breach risk if sustained
Negative ROE of -18.7% and ROA of -7.9% suggest asset impairments or stranded capacity that may require write-downs
Debt-to-equity of 1.02 limits financial flexibility for countercyclical investments or working capital expansion during recovery
The 93.5% stock price decline may indicate undisclosed operational issues, customer losses, or environmental liabilities not reflected in reported financials
high - Demand for specialty chemical intermediates is highly correlated with end-market industrial activity. Agrochemical demand links to agricultural GDP and farmer income levels. Pharmaceutical intermediate demand ties to generic drug production cycles. Dye intermediate demand correlates with textile manufacturing activity, which is cyclical and export-dependent. The -12.3% revenue decline suggests current weakness in one or more end-markets. Industrial production indices and manufacturing PMI are leading indicators for order flow.
Rising interest rates negatively impact the company through higher debt servicing costs on the 1.02 D/E ratio and reduced valuation multiples for capital-intensive businesses. With negative free cash flow, the company may require refinancing or additional borrowing, making rate increases particularly painful. Customer capex decisions in agrochemical and pharmaceutical sectors also become more conservative in high-rate environments, potentially delaying orders.
High credit exposure given negative free cash flow, elevated capex, and moderate leverage. The company requires access to working capital facilities for raw material procurement and finished goods inventory. Tightening credit conditions or rising spreads would increase financing costs and potentially constrain operations. The current ratio of 1.51 provides modest liquidity cushion, but negative operating cash flow conversion raises refinancing risk.
value/distressed - The 0.2x price-to-book and 0.6x price-to-sales ratios suggest deep value or distressed characteristics. Current investors are likely contrarian value players betting on operational turnaround, asset recovery, or restructuring. The negative free cash flow and ROE deter growth and quality-focused investors. High volatility and execution risk make this suitable only for investors with high risk tolerance and ability to assess turnaround probability.
high - The 75.8% three-month decline and 93.5% one-year decline indicate extreme volatility driven by operational distress, liquidity concerns, or company-specific issues. Beta is likely 1.5-2.0x relative to Indian small-cap indices. Daily price swings of 5-10% are common in distressed specialty chemical stocks with low float and institutional selling pressure.